A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab

BACKGROUND: Transgenic adoptive cell therapy (ACT) targeting the tumor antigen NY-ESO-1 can be effective for the treatment of sarcoma and melanoma. Preclinical models have shown that this therapy can be improved with the addition of dendritic cell (DC) vaccination and immune checkpoint blockade. We...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Nowicki, Theodore S., Berent-Maoz, Beata, Cheung-Lau, Gardenia, Huang, Rong Rong, Wang, Xiaoyan, Tsoi, Jennifer, Kaplan-Lefko, Paula, Paula Cabrera, Tran, Justin, Pang, Jia, Macabali, Mignonette, Garcilazo, Ivan Perez, Carretero, Ignacio Baselga, Kalbasi, Anusha, Cochran, Alistair J., Grasso, Catherine S., Hu-Lieskovan, Siwen, Chmielowski, Bartosz, Comin-Anduix, Begoña, Singh, Arun, Ribas, Antoni
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445780/
https://ncbi.nlm.nih.gov/pubmed/30573690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3496
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller